Ankylosing Spondylitis
                            Targeting Interleukin Pathways for Early and 
                            Aggressive Disease Management
                            September 17, 2020
                            ©© 2 2002200. . AllAll  rrigighthtss r reserveserved.ed.                                                                                                           © 2020. All rights reserved. 
                            No No paparrtt  oof f tthihiss r repoeporrtt  mmay ay be be rrepreprooduduced ced oorr  didissttrribibututed ed witwithohoutut                                     No part of this report may be reproduced or distributed without the 
                            tthe ehe expxprressessed ed wrwritittten en perpermmisisssioion n oof f PTPTCE.CE.                                                                                 expressed written permission of PTCE.  
              Ankylosing Spondylitis: 
      Targeting Interleukin Pathways for Early 
       and Aggressive Disease Management
                  Susan P. Bruce, PharmD, BCPS
                 Senior Associate Dean of Education
                  Professor of Pharmacy Practice
                 Northeast Ohio Medical University 
                     College of Pharmacy
                      Rootstown, Ohio
  Understanding the Pathophysiology 
    of Ankylosing Spondylitis
                    Patient Case
    • A 28-year-old man presents to his PCP with continued complaints of low back pain. 
     Following his appointment 3 months ago, he started taking ibuprofen 800 mg 3 times 
     daily with minimal relief. Though the pain has been bothering him for about 2 years, 
     his first visit with his PCP was 6 months ago. He rates his pain as a 7 on a scale of 0-
     10.
    • His ASDAS-CRP score today is 2.8
    • He is otherwise healthy and does not take prescription medications